



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Nyvepria

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
N/0012	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	24/03/2023		PL	
IB/0010	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	05/01/2023	n/a		

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



PSUSA/2326/ 202201	Periodic Safety Update EU Single assessment - pegfilgrastim	29/09/2022	n/a		PRAC Recommendation - maintenance
IB/0009	B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS	28/07/2022	n/a		
IA/0007	B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol	06/12/2021	n/a		
IA/0006	A.7 - Administrative change - Deletion of manufacturing sites	25/10/2021	13/06/2022	Annex II	
IB/0005	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	01/07/2021	13/06/2022	SmPC and PL	
II/0002/G	This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.f - Change in the manufacturer of AS or of a	24/06/2021	n/a		

	<p>starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p> <p>B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p>				
IB/0004	B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation	31/05/2021	n/a		
IB/0003	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	29/04/2021	13/06/2022	SmPC and PL	
N/0001	Minor change in labelling or package leaflet not	04/03/2021	13/06/2022	PL	

	connected with the SPC (Art. 61.3 Notification)				
--	---	--	--	--	--